According to Zacks, “Orion Oyj is a pharmaceutical company. It develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company’s core therapy consists of central nervous system disorders, oncology and respiratory. Its product pipeline includes inhaled Easyhaler(R) pulmonary drugs. Orion Oyj is headquartered in Espoo, Finland. “
Shares of ORINY opened at $25.05 on Wednesday. ORION OYJ/ADR has a 12-month low of $18.65 and a 12-month high of $27.00. The company has a quick ratio of 1.97, a current ratio of 2.98 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $7.08 billion, a price-to-earnings ratio of 24.56 and a beta of 0.65. The stock’s 50-day moving average price is $24.74 and its 200 day moving average price is $21.65.
ORION OYJ/ADR (OTCMKTS:ORINY) last issued its quarterly earnings results on Friday, July 17th. The company reported $0.30 earnings per share (EPS) for the quarter. ORION OYJ/ADR had a return on equity of 34.03% and a net margin of 22.98%. The firm had revenue of $322.01 million for the quarter. Equities research analysts expect that ORION OYJ/ADR will post 0.82 EPS for the current year.
About ORION OYJ/ADR
Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs.
Recommended Story: Is the QQQ ETF safe?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ORION OYJ/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORION OYJ/ADR and related companies with MarketBeat.com's FREE daily email newsletter.